Share-based Payment Arrangement, Expense of Syros Pharmaceuticals, Inc. from 31 Dec 2014 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Syros Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2024.
  • Syros Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $1,625,000, a 50% decline year-over-year.
  • Syros Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $7,251,000, a 38% decline year-over-year.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10,434,000, a 8.6% decline from 2022.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11,410,000, a 10% increase from 2021.
  • Syros Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $10,354,000, a 5.3% decline from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Syros Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $7,251,000 $1,625,000 -$1,630,000 -50% 01 Jul 2024 30 Sep 2024 10-Q 31 Oct 2024 2024 Q3
Q2 2024 $8,881,000 $1,803,000 -$1,011,000 -36% 01 Apr 2024 30 Jun 2024 10-Q 31 Jul 2024 2024 Q2
Q1 2024 $9,892,000 $2,103,000 -$542,000 -20% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $10,434,000 $1,720,000 -$1,183,000 -41% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2024 2023 FY
Q3 2023 $11,617,000 $3,255,000 +$300,000 +10% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $11,317,000 $2,814,000 +$125,000 +4.6% 01 Apr 2023 30 Jun 2023 10-Q 31 Jul 2024 2024 Q2
Q1 2023 $11,192,000 $2,645,000 -$218,000 -7.6% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $11,410,000 $2,903,000 +$28,000 +0.97% 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $11,382,000 $2,955,000 +$859,000 +41% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $10,523,000 $2,689,000 +$236,000 +9.6% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $10,287,000 $2,863,000 -$67,000 -2.3% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $10,354,000 $2,875,000 -$155,000 -5.1% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 $10,509,000 $2,096,000 -$627,000 -23% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $11,136,000 $2,453,000 -$274,000 -10% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $11,410,000 $2,930,000 +$471,000 +19% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $10,939,000 $3,030,000 -$185,000 -5.8% 01 Oct 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
Q3 2020 $11,124,000 $2,723,000 +$334,000 +14% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $10,790,000 $2,727,000 +$371,000 +16% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $10,419,000 $2,459,000 +$580,000 +31% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $9,839,000 $3,215,000 +$1,582,000 +97% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2022 2021 FY
Q3 2019 $8,257,000 $2,389,000 +$852,000 +55% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $7,405,000 $2,356,000 +$612,000 +35% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $6,793,000 $1,879,000 +$183,000 +11% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $6,610,000 $1,633,000 +$362,000 +28% 01 Oct 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
Q3 2018 $6,248,000 $1,537,000 +$429,000 +39% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $5,819,000 $1,744,000 +$588,000 +51% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $5,231,000 $1,696,000 +$812,000 +92% 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019 2019 Q1
Q4 2017 $4,419,000 $1,271,000 +$541,000 +74% 01 Oct 2017 31 Dec 2017 10-K 05 Mar 2020 2019 FY
Q3 2017 $3,878,000 $1,108,000 -$586,000 -35% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $4,464,000 $1,156,000 +$8,000 +0.7% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $4,456,000 $884,000 +$222,000 +34% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $4,234,000 $730,000 01 Oct 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
Q3 2016 $1,694,000 +$433,000 +34% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $1,148,000 +$535,000 +87% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $662,000 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q3 2015 $1,261,000 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 $613,000 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2016 Q2

Syros Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $10,434,000 -$976,000 -8.6% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2024 2023 FY
2022 $11,410,000 +$1,056,000 +10% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $10,354,000 -$585,000 -5.3% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 $10,939,000 +$1,100,000 +11% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $9,839,000 +$3,229,000 +49% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $6,610,000 +$2,191,000 +50% 01 Jan 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
2017 $4,419,000 +$185,000 +4.4% 01 Jan 2017 31 Dec 2017 10-K 05 Mar 2020 2019 FY
2016 $4,234,000 +$1,001,000 +31% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
2015 $3,233,000 +$2,296,000 +245% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $937,000 01 Jan 2014 31 Dec 2014 10-K 20 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.